Corteva, Inc. (CTVA) Q3 2025 Earnings Call Transcript
Corteva, Inc. ( CTVA ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Kimberly Booth - Vice President of Investor Relations Charles Magro - CEO & Director David Johnson - Executive VP & CFO Robert King - Executive Vice President of Crop Protection Business Unit Judd O'Connor - Executive Vice President of Seed Business Unit Conference Call Participants Christopher Parkinson - Wolfe Research, LLC Vincent Andrews - Morgan Stanley, Research Division Kevin McCarthy - Vertical Research Partners, LLC Joel Jackson - BMO Capital Markets Equity Research David Begleiter - Deutsche Bank AG, Research Division Joshua Spector - UBS Investment Bank, Research Division Jeffrey Zekauskas - JPMorgan Chase & Co, Research Division Daniel Rizzo - Jefferies LLC, Research Division Patrick Fischer - Goldman Sachs Group, Inc., Research Division Arun Viswanathan - RBC Capital Markets, Research Division Aleksey Yefremov - KeyBanc Capital Markets Inc., Research Division Kristen Owen - Oppenheimer & Co. Inc., Research Division Matthew DeYoe - BofA Securities, Research Division Patrick Cunningham - Citigroup Inc., Research Division Edlain Rodriguez - Mizuho Securities USA LLC, Research Division Benjamin Theurer - Barclays Bank PLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin and I will be your conference operator today.
Corteva, Inc. (CTVA) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Corteva, Inc. (CTVA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Corteva, Inc. (CTVA) Reports Q3 Loss, Tops Revenue Estimates
Corteva, Inc. (CTVA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.
Corteva, Inc. (CTVA) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Corteva, Inc. (CTVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Corteva, Inc. (CTVA) Expected to Beat Earnings Estimates: Should You Buy?
Corteva, Inc. (CTVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Corteva, Inc. (CTVA) is Poised to Beat Earnings Estimates Again
Corteva, Inc. (CTVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Despite Corteva Dividing In Two, The Preferreds Now Get A Strong Buy Rating
Corteva, Inc. is splitting into two companies, creating uncertainty but maintaining strong equity coverage for its preferred stocks. The preferred stocks, CTA.PR.A and CTA.PR.B, will remain with the new Corteva entity, which retains 44% of current sales and global diversification. Both preferreds offer investment-grade ratings, cumulative dividends, and low call risk, making them attractive for portfolio diversification.
Is Corteva (CTVA) Stock Outpacing Its Consumer Staples Peers This Year?
Here is how Corteva, Inc. (CTVA) and Local Bounti Corporation (LOCL) have performed compared to their sector so far this year.
Here's Why Corteva, Inc. (CTVA) is Poised for a Turnaround After Losing 15% in 4 Weeks
Corteva, Inc. (CTVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More
The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon, as a federal government shutdown took effect.
Corteva: Premium Valuation Justified By Earnings Quality
Corteva is rated a Buy with a 12.7% upside to a $80 target, driven by strong market leadership and operational efficiency. CTVA's dual-segment strategy and innovation in seeds and crop protection underpin resilient earnings and robust margin expansion in 2025. Upgraded 2025 guidance, strong free cash flow, and disciplined capital allocation support premium valuation and ongoing shareholder returns.
Corteva, a $50 Billion Seed-and-Pesticide Maker, Is Exploring a Breakup
A breakup of the $50 billion seed-and-pesticide maker could usher in a dealmaking wave in agriculture not seen since the first Trump administration.
